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vinyl-terminated linear siloxane which while decomposing during pyrolysis generates pores with size propor-
tional to the molecular weight), followed by a post-pyrolysis etching treatment by hydrofluoric acid (HF) to ob-
tain C-rich SiOC samples having additional micro-/mesoporosity and specific surface area reaching to 774 m2/g.
The biocompatibility of the samples was validated by hemolysis test, and their cargo/drug loading capacities
were studied by two different sized polypeptides asmodelmolecules. SiOC particles showed less hemolysis com-
pared to the reference material MCM-41. Similarly, the loading capacity and the release kinetics of bovine serum
albumin (BSA) and vancomycin-loaded SiOC particles were improved compared to that of MCM-41. In the multi
cargo loading/release capacity tests, done by using different sizedmolecules, Bio2-HF and MCM-41 were loaded
bothwith fluorescein and BSA.While a lagging time in fluorescein release was observed for MCM-41, the release
kinetics of fluorescein and BSA was not affected when they are loaded together in the hierarchical pores of Bio2-
HF, allowing the release of both large and small cargo molecules. The antimicrobial activity tests showed that
Bio2-HF performed better than MCM-41 particles in improving bactericidal activity.
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Numerous processing routes have been explored for the production
of porous ceramics, and several reviews are already available on the
subject [1–5]. In order for a porous component to possess a wide
range of characteristics, such as rapid transport, high selectivity, fast up-
take and release, etc. it should comprise an interconnected cellular
framework of different pore scales, i.e. hierarchical porosity [3]. Differ-
ent types of hierarchical porosity may exist, according to the range of
pore sizes that are involved in the porous structure, i.e. bimodal size dis-
tribution (micro-meso, meso-macro, micro-macro), or trimodal (micro-
meso-macro). The presence of “small” pores (particularly micropores,
pores b2 nm) provides a high SSA (specific surface area) i.e. geometric
area per unit mass of the part making the material functioning for a
given application while macropores (pores N 50 nm) offer mechanical
stability as well as high transfer rate.
Hierarchical porosity components have also been investigated quite
extensively [6–16]. Those studies have shown that the use of
preceramic polymers offers advantages to create such porous structures
since it is possible to use awide range ofmethods borrowed either from
low-cost plastic forming techniques such as extrusion, melt spinning,
injection molding, blowing, etc. or from advanced ones such as additive
manufacturing, electrospinning or aerogel processing [3,17–20].
Biocompatible material performs a medical therapeutic function
without undesirable local or systemic effects in the patient [21]. Drug
delivery systems are biocompatible carriers used for the targeted deliv-
ery/controlled release of therapeutic drugs [22,23]. For example, site-
specific and rate-controlled release of antibiotics can be innovative de-
livery systems to combat the increasing antibiotic resistance develop-
ment problem. Accordingly, controlled release of antibiotics such as
vancomycin, a glycopeptide antibiotic that is used to treat infections
caused byGrampositive bacteria, has been explored to increase drug ef-
ficacy and patient compliance.
Among the drug delivery systems developed, mesoporous silica
nanoparticles (MSN), especially MCM-41 and SBA-15, have been exten-
sively exploited for controlled drug release systems [23,24]. These high
surface area mesoporous materials, generally speaking, are constituted
by monomodal porosity which could be tailored to some extend in the
mesopore range (2–50 nm) [25]. Yet hierarchically architectured porous
silica particles, seen in the nature, have rarely beenused for such purpose
[26]. Various drugmolecules have been hosted byMSN particles synthe-
sized with several different methods [23]. Apart from MSN, other inor-
ganic porous materials such as zirconia, alumina, titania, etc. have also
been produced for potential drug delivery systems [27]. In a recent
study, Tamayo et al. [28] prepared a bimodal mesopore size distribution
polymer derived ceramic (PDC); silicon oxycarbide (SiOC), functional-
ized with amino groups, and studied the release kinetics of Tenofovir
cargo. However, despite extensive research on preceramic polymers
and related PDCs, these materials were seldom tested in other medical
applications [29–31]. Silicon oxycarbide is an anionic modification of sil-
ica glass in which part of the divalent oxygen atoms are substituted by
tetravalent carbon atoms. This structural modification results into im-
proved mechanical, chemical and thermal properties compared to the
parent SiO2 glass [32].
Aforementioned studies have typically attempted to develop a carri-
er system to load a single drug, however loading a single cargo may not
suffice to achieve ideal therapeutic efficacy, as in the case for chemo-
therapeutic drugs. As known, for the treatment of metastatic cancers a
resistance to single agent occurs, and it can be overcome by combina-
tion chemotherapy usingmultiple anticancer agents producing a syner-
getic effect [33]. While dual/multi cargo carrier related works recently
have been reported in the literature [33–35], such works used mesopo-
rous particles (e.g. MSN). Similarly, albeit hierarchicalmaterials exhibit-
ed promising bio-properties, to the best of our knowledge, there is no
other study that focused on the deliberate formation of hierarchical po-
rosity materials such as the ones proposed in this study, i.e. C-rich SiOC,and tested them with two very different sized cargo molecules for dual
cargo delivery applications.
In the present work, following a relatively simple synthesis route,
pristine SiOC samples designed to be mesoporous or just being non-
porous have been obtained. Silica regions of these samples were further
etched by hydrofluoric acid (HF) to obtain C-rich SiOC comprising addi-
tional micro-/mesoporosity and high SSA. These hierarchically porous
SiOC samples were studied to demonstrate that a material with hierar-
chical porosity can be a promising platform to carry multiple drugs
(cargo molecules) simultaneously, i.e. as an alternative drug delivery
material which can carry and release cargo combination simultaneous-
ly. The samples were investigated for hemocompatibility, loading ca-
pacity with two different sized polypeptides (vancomycin or
fluorescein and bovine serum albumin, BSA) as model cargo (drug)
molecules, and antimicrobial activity. Commercially available mesopo-
rous silica (MCM-41) was also characterized as reference material [25].
2. Experimental procedure
2.1. Materials
Mesoporous silica (MCM-41)was purchased fromSigma (CAS#7631-
86-9, Sigma-Aldrich, Munich, Germany). Polymethylhydrosiloxane
(Gelest, PHMS, MW~2100–2400, 30–45 cST, CAS# 63148-57-2, Gelest,
Morrisville, PA, USA) having Si\\H bonds, vinyl-terminated polydimeth-
ylsiloxane (PDMS, MW:62700, 10000 cSt, CAS# 68083-19-2, Gelest,
Morrisville, PA, USA) and a cyclic 2,4,6,8-tetramethyl-2,4,6,8-
tetravinlycyclotetrasiloxane (TMTVS 97%, Alfa Aesar, Ward Hill, MA,
USA, CAS# 2554-06-5) with Si-C_C moieties, were used as preceramic
precursors together with platinium - divinyltetramethyldisiloxane com-
plex, ~Pt 2% in xylene (CAS# 68478-92-2, Sigma-Aldrich, St. Louis, MO,
USA) serving as catalyst for the curing reactions. Hydrotalcite, (LDH
with a chemical formula of Mg6Al2(CO3)(OH)16·4H2O, CAS# 11097-59-
9, Sigma-Aldrich, St. Louis, MO, USA), was used as received.
PHMS/LDH/PDMS/TMTVSwhen 1/0.055/0.25/1 the sample coded as
Bio1, and when 1/0.055/1/1 the sample coded as Bio2. The chemicals
(all in mass ratio) were put into a glass beaker and mixed under mag-
netic stirring at room temperature (RT) for 5 min at 500 rpm until the
homogeneous mixture was achieved. Upon homogenization, 100 ppm
by weight of Pt relative to PHMS was added into the mixture in a
drop-wise manner. The blend was further mixed at 500 rpm for
25 min, and transferred into aluminum molds standing on the hot
plate operating at 200 °C for curing overnight, followed by pyrolysis in
an alumina tubular furnace (PROTERM PTF 16/75/450, Ankara,
Turkey) at 1300 °C with a heating rate of 2 °C/min and 1 h dwell time
at the maximum temperature under N2 gas flow (100 ml/min). The
etching process was conducted on ca 250 mg of SiOC bulk sample
using 50 ml of HF (48 vol% in H2O) solution in PE closed containers
[36]. The attack was performed by leaving the sample in contact with
the etching solution for 4 days at RT and gently stirring the containers
by hand time to time. After the attack, SiOC sampleswerefiltered, rinsed
with distilled water (several times) and dried at 65 °C for 24 h for the
subsequent analysis.
2.2. Characterization
The morphological features were analyzed from fresh fracture sur-
faces using a Scanning Electron Microscope (SEM, FEI-Philips XL30
ESEM-FEG) after 10 nm Pt film deposition by sputtering. For Transmis-
sion Electron Microscopy (TEM, Philips CM12 (The Netherlands), tung-
sten thermionic source, 120 kV accelerating voltage) the samples were
ground in an agate mortar and dispersed in ethanol for 5 min. A drop
of solution was placed onto a carbon coated copper grid, followed by
drying and analysis. X-ray diffraction data (XRD, Rigaku, DB-max)
were collected using Cu Kα1 radiation (40 kV, 30 mA, step scan of
0.05°, counting time of 3 s/step). Both the un-etched and etched
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were collected at 77 K using anASAP 2010 (Micromeritics, Norcross, GA,
USA) after degassing the sample at 200 °C forminimum4 h before anal-
ysis. SSAwas calculated from a BET (Brunauer, Emmet, and Teller) anal-
ysis in the P/P0 range of 0.05–0.30 using a minimum of five data points.
The pore size distributions (PSDs) were obtained from the desorption
branch of the isotherm through the BJH (Barret, Joyner, and Halenda)
analysis.
2.3. Hemolysis
Whole human blood was collected and used within 8 h. About 1 ml
of whole blood was added to 8 ml of Dulbecco's phosphate buffered sa-
line (D-PBS) and the Red Blood Cells (RBCs) were isolated from serum
by centrifugation at 10,000 ×g for 1 min. The RBCs were washed two
times with D-PBS solution. Finally, the RBCs were diluted to 1 ml of D-
PBS. For each experiment, 50 μl of the diluted RBC suspension was
added to 50 μl of silica or SiOC particle suspension in D-PBS at the con-
centration of 1.0 mg/ml and incubated for 4 h with shaking. After that,
themixture was centrifuged and the supernatants were assayed for he-
moglobin content by Drabkin's method [37] by measuring the absor-
bance value at 577 nm with the reference wavelength at 655 nm. All
samples were prepared in triplicate. The percent of hemolysis was cal-
culated as: (Hemolysis % = [(Sample absorbance− negative control)/
(positive control− negative control)] × 100%).
2.4. Time-kill curves
The bacterial susceptibility was studied by determining minimal in-
hibitory concentrations (MICs) in 96-well microtiter plates using the
broth microdilution method as described in the clinical and laboratory
standards institute [38]. Mueller Hinton Broth (MHB) was used for sus-
ceptibility testing as it is the common medium used for Staphylococcal
cultures [39].
2.5. Loading & release
SiOC or MCM-41 particles were loaded with BSA and/or vanco-
mycin by incubating in 2 mg/ml BSA and 100 μM vancomycin in
PBS overnight. The mixture was then washed with PBS before it is
used in the experiments. Release of vancomycin from pores was
monitored in a UV/VIS spectrophotometer (Agilent, 8000, Santa
Clara, USA) at 280 nm as described [39]. BSA release was monitored
by Bradford protein assay [40]. The particles were incubated for the
required time in PBS buffer and the supernatants obtained after cen-
trifugation at 12000 rpm for 1 min were assayed for vancomycin or
BSA. The solution was stirred continuously to create a homogeneous
solution during incubation. The maximum loading of the particles
with vancomycin or BSA was determined by preparing a mixture of
1mg particle mixture in PBS buffer andmeasuring the 280 nm absor-
bance in a well-mixed solution.
3. Results and discussion
3.1. Morphological characterization
Small sized (b1 mm) pieces were used in HF etching and following
cargo release tests. In Fig. 1 (a–d) such pieces obtained from the sample,
before (Bio1) and after HF (Bio1-HF) etching, are shown. While at the
lower magnification (Fig. 1 (a & b)) similar structures can be observed,
comparing the higher magnification images given in Fig. 1(c) and
(d) taken from the samples before and after etching respectively, the ef-
fect of acid treatment can evidently be seen. The roughness increases
consistently with the formation of nano-sized pores upon acid
treatment.Fig. 2(a), (b) and (c) shows the TEM image of MCM-41, Bio1-HF and
Bio2-HF, respectively. The differences in pore structures can evidently
be seen.MCM-41 is constituted bywell-definedmonomodalmesopores
below 5 nm in diameter (see later for N2 ads./des. data), instead in HF
treated SiOC samples, there are different sized mesopores (from 2 to
50 nm) together with macropores bigger than 50 nm. Besides, sample
Bio2-HF demonstrates higher number of large sized mesopores com-
pared to Bio1-HF. Concerning the applications, such type of porosity
character is important since it is known that macroporous framework
provides high external mass transfer rate due to interconnections be-
tween the channels, and low pressure drop, while the micro/mesopo-
rous system provide the functionality (bio-for the present case) for a
given application.
1.1. Structural characterization
1.2. Porosity characterization
We have synergistically combined two approaches to prepare po-
rous SiOC bodies: (i) utilization of PDMS (vinyl-terminated) for the pur-
pose of “molecular spacer” to promote the formation of pores in the
10–20 nmrange after pyrolysis [41], and (ii) a post-pyrolysis HF etching
to dissolve the silica clusters present in the SiOC microstructure [5,42,
43] forming pores below 5 nm in size. The vinyl-terminated linear
PDMS bonds with the pre-ceramic polymer (PHMS) and acts as a “mo-
lecular spacer” pushing apart the PHMS chains. During pyrolysis the
PDMS decomposes completely creating pores whose size is related to
the PDMS molecular weight [41]. It is known from the literature that
the MW of the PDMS used in this study should lead to the formation
of pores in the range 10–30 nm. Indeed, as could be seen from the
Table 1, with increasing the PDMS amount, the SSA values increased
even without HF treatment. When the sample was made by using 0.25
parts of PDMS (i.e. Bio1), the resulting SSA was only 4.3 m2/g but qua-
drupling PDMS in the blends (Bio2, i.e. 1 part PDMS with 1 parts
PHMS) the SSA of 121.9 m2/g was obtained, similar to previous work
[44]. Comparable SSA increase due to additionally formedmesoporosity
was also observed in previous studies [41,45].
The N2 adsorption-desorption isotherms (not shown for brevity) re-
corded on the reference MCM-41 sample show the typical shape of
mesoporous materials with the hysteresis loop close to P/P0 = 0.4 sug-
gesting the presence of pores of ~3 nm size, in agreementwith the pub-
lished literature [46,47]. The BET surface area and total porosity values
measured for the MCM-41 silica sample are 744 m2/g and 0.914 cm3/g
as also reported in Table 1.
The sorption isotherms recorded on the samples before and after HF
attacks are reported in Fig. 3(a). While sample Bio1 shows almost flat
sorption isotherm typycal of low porosity material with the increase
in PDMS amount, a clear hystherisis loop appears above 0.8 P/P0 indicat-
ing the presence of meso-macroporosity in the sample, see Fig. 3(a).
After HF etching all these isotherms change, showing a steep increase
at P/P0 b 0.1 identifying microporosity which additionally formed dur-
ing acid treatment. Indeed it is demonstrated that silicon oxycarbide
have a complex nanostructure with a SiO2-rich and a C-rich interpen-
etrating nano-sized networks [48,49]. The silica rich “phase” can be
etched outwith a post-pyrolysis treatmentwithHF leaving behind a po-
rous network whose typical size is a function of themaximumpyrolysis
temperature and time [50].
In Fig. 3(b) pore volume vs. pore size curves are given. While the
sample with low amount of PDMS (Bio1) shows almost no meso-
macroporosity measured by N2 sorption test, increasing the PDMS frac-
tion (Bio2) resulted in the formation of mesopores in the 10–20 nm size
range [41,44]. After HF etching, samples showed three-modal pores,
namely: micropores below 2 nm, pores having ~4–5 nm similar to pre-
viously work [51], and while the intensity is not as high as before, pores
with sizes larger than 5 nm up to ~50 nm, i.e. hierarchical porosity,
corraborating TEM data.
cb
d
a
Fig. 1. SEM images taken from the fracture surfaces of pyrolyzed sample (Bio1), (a) before HF etching, (b) after HF etching. Highermagnification images showing surface details, (c) before
HF etching, and (d) after HF etching.
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Most of the biomedical applications of nanoparticles involve a direct
contact with blood. Thus, hemocompatibility studies have frequently
been investigated to understand blood-compatible behavior of the po-
tential application. The hemolytic activity of samples was determined
by spectroscopic assay to measure hemoglobin amount, which is a di-
rect indication of the integrity of RBCs. Although we used MCM-41 par-
ticles for comparison purposes, they are not similar in size or shape.
However, they are themost suitable particles to be compared for hemo-
lysis properties. As shown in Fig. 4(a), the hemolytic properties of
SiOC particles were lower than that of the silica (MCM-41). Bio1 result-
ed in the least hemolytic activity among all the studied SiOCba
Fig. 2. TEM images taken from (a) MCMparticles, which was 31% of the value measured for the MCM-41.
Fig. 4(a) shows that HF etching treatment resulted in an increase in
the hemolytic activity of SiOC particles, yet less hemolytic than MCM-
41 particles. Bio2-HF was the most hemocompatible among HF etched
samples with a hemolytic activity of 18% less compared to MCM-41. It
is highly probable that these results are related with two factors;
(i) specific surface area, and (ii) surface silanol density [52]. The increase
in surface area, enhances the contact with RBCs therefore may rise the
hemolytic activity, but more pronounced effect comes from the latter.
For all SiOC system investigated (both for etched and not-etched),
there were fewer “accessible” Si-OH groups, i.e. the surface density of
silanol groups were lower in SiOC compared to MCM-41. It should be
underlined that HF treatment creates additional micro-mesoporosityc
-41, (b) Bio1-HF, and (c) Bio2-HF.
Table 1
Summary of the N2 sorption test results from all samples (uncertainties for SSA values are given based on BET multiple linear regression). Note that data for Bio1 and Bio2 are reprinted
with permission from ref. [44].
BET (m2/g) Micropore volume (cm3/g) Pore volume (cm3/g) - BJH desorption cumulative volume of pores
Bio1 4.3 ± 0.03 0.001 0.023
Bio2 121.9 ± 0.2 0.004 0.473
Bio1-HF 774 ± 13 0.363 0.441
Bio2-HF 663 ± 7.5 0.139 0.581
MCM-41 744 ± 10 0.161 0.914
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are being created [20,53]. Such process is actually a simple alternative
way of surface functionalizationwhile tailoring surface area, surface en-
ergy and nanorugosity index; it eventually enhances the interaction be-
tween the cargo molecule (i.e. drugs) and host surface.
The loading capacity of the particles is another important parameter
in medical applications. In this study, two polypeptides with different
size were employed as model cargo molecule to study the effects of hi-
erarchical porosity properties. Bovine Serum Albumin (BSA) is the
major blood serum protein, frequently employed as model peptide in
medical research. With 1.4 × 4.0 × 4.0 nm3 dimensions, it consists of
589 amino acidsmaking amolecularweight (MW) of 66,463 Da. Vanco-
mycin is a glycopeptide has antibiotic properties and it is about 20 times
smaller in volume than BSA with dimensions of 0.8 × 1.5 × 1.0 nm3
(MW of 1449.3 Da) [54].
The results in Fig. 3(b) showed that Bio2-HF particles demonstrated
higher loading capacity, compared to particles with only mesopores
(MCM-41). The hierarchical SiOC particles seem to be suitable for med-
ical application with higher loading capacity both for small peptide,
vancomycin and for a large protein, BSA. 1 mg of Bio1 could adsorb
13 pmol of BSA, and HF-etching increased the adsorption capacity to
49 pmol. With a higher capacity, one mg of Bio2 particle adsorbed
31 pmol BSA, and after HF-etching 180 pmol BSA was loaded. Instead,
mesoporous silica control sample MCM-41 adsorbed 47 pmol BSA. In
all samples tested, vancomycin adsorption was at lower levels com-
pared to BSAmolecules, which can be explained by different interaction
opportunities with the surface, resulting frommore contact sites in BSA
[55,56]. Bio1 adsorbed 4 and 8 pmol vancomycin, respectively before
and after HF-etching. Similarly, HF-etching increased vancomycin load-
ing capacity of Bio2-HF about two times from 8 to 19 pmol while MCM-
41particles could adsorb 14 pmol. In summary, Bio2-HF adsorbed about
3.8 times more BSA and about 1.4 times more vancomycin molecules
than that of MCM-41. The reason behind such an observation lies in:
(i) surface chemistry, which seems not suffice to explain the differences
in the adsorption capacity of the Bio1-HF and Bio2-HF since surfaceFig. 3.N2 adsorption-desorption recorded on the samples; (a) adsorption-desorption isotherm
curves calculated from the desorption branchof the isotherms. Note that data for Bio1 and Bio2 a
characteristics after HF attack.chemistry of these etched samples should be quite similar, and (ii) dif-
ferences in pore characteristics, the pore volume of Bio2-HF is much
higher than that of Bio1-HF, besides the majority of the porosity for
Bio2-HF localized in the 3–10 nm range which seems to be a very func-
tional pore architecture to adsorb such molecules, yet for Bio1-HF, the
porosity is spread over a wide range, see Fig. 3(b). Note also that
MCM-41 has monomodal porosity around ~3 nm.
3.3. Drug release
BSA is a globular protein that is commonly used in the biochemical
applications. Bradford protein determination assay is based on absorp-
tion maximum of Coomassie Brilliant Blue associated with peptide
bonds. The BSA concentrations in release experimentswere determined
by comparing to standard BSA concentrations. Vancomycin is a short
peptide, consisting of two kinds of amino acids, namely Alanine and Ly-
sine. Peptide bond absorbs strongly in the far UV regionwith an absorp-
tion band at 280 nm that can be used to calculate molar extinction
coefficient according to Beers-Lambert law. The vancomycin concentra-
tions in release experiments were determined by comparing to stan-
dard vancomycin concentrations. Cargo loading values were already
supplied in Fig. 4(b).
Cargo release properties of sampleswerefirst tested in vitro bymon-
itoring BSA or vancomycin release by UV absorbance method. The par-
ticles loaded with either vancomycin or BSA was incubated in PBS
buffer. The cumulative release of cargo increased up to 5 h and leveled
off afterwards. MCM-41 particles released about 78% of loaded BSA in
4.5 h and 80% at the end of one day incubation (Fig. 5(a)). Bio2 particles
demonstrated a similar release profile with 78% release in 4.5 h while
Bio1 particles showed slightly slower release rate with 65% release in
4.5 h (Fig. 5(a)). However, for the etched samples, the release amount
increased, for Bio2-HF to 86% for initial 4.5 h and 90% for one-day
incubation.
The amount of vancomycin release fromMCM-41 reached to 78% in
4.5 h, which is in agreement with previous reports [57], and analogouss before and after HF etching, and (b) corresponding pore volume vs pore size distribution
re reprintedwith permission from ref. [44] in order to show the transformation of the pore
Fig. 4. (a) Hemolysis (Drabkin's method) of Human RBCs by hierarchical SiOC and mesoporous silica particles (MCM-41), and (b) the amount of protein cargo loading (Vancomycin or
BSA) to each particle was given as pmole.
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Bio2 with or without HF-etching) have shown comparable release pro-
files with initial fast release followed by a slower release step; see
Fig. 5(b). Among all samples, however, HF treated samples behaved dif-
ferently showing fewer release of vancomycin after initial fast release
stage than that of MCM-41 (and also around same amount less com-
pared to BSA molecules).
It was recently shown that the pore size is an important parameter
in determining the drug release kinetics from mesoporous silica parti-
cles [58]. However, not only pore size but also molecule chemistry and
size (weight) of the used cargo should be critical (different end groups
from these cargo molecules may exert additional interactions). Due
probably to this mutual interaction between vancomycin molecules
and hierarchical porosity and surface chemistry provided in HF treated
samples, a longer release profile resulting in about 20% less release of
cargo in 24 h, compared to MCM-41, was observed. This is a significant
finding since with such hierarchical porosity materials; diverse cargo
molecules having different release kinetics could be delivered at the
same time.
Dual/multi cargo loading related works recently seen in the litera-
ture [33,34,59], only focused on the utilization of mesoporous nanopar-
ticles (the used MSN particles are mostly having gradient porosity in
meso-scale but they do not have hierarchical porosity by definition). Hi-
erarchically porous materials such as SiOC particles produced in the
present work, were never used before and could perhaps bemore func-
tional in multi drug delivery therapies. Another important point should
also be underlined: in the reported studies for dual cargo release, similar
sized cargomoleculeswere utilized. For example, Song et al. [59] report-
ed dual delivery of fluorescein and rhodamine B (MW of 332.3 and
479 Da, respectively). Li et al. [33] used silica nanoparticles for co-
delivery of doxorubicine (MW of 543.5 Da) and and cisplatinFig. 5. Release curve of (a) BSA, and (b) vanco(300 Da). Fluorescein molecules are documented to be oblate ellipsoid
with approximated volume of 0.4 nm3, other molecules with compara-
ble MWs are expected to be in the similar size range [60].
In order to show the capabilities of hierarchically porous SiOC parti-
cles, fluorescein and BSA molecules were used as model cargos. Differ-
ent than those mentioned studies, we chose extreme molecular sized
cargo molecules in order to demonstrate capabilities of hierarchically
porous materials for co-delivery of molecules having diverse sizes. In
dual release studies, the cargo vancomycin was replaced by fluorescein
for easy and sensitive detection properties. Fluorescein (~0.4 nm3 &
332.3 Da), selected as a model for small sized drugs, is a water soluble
molecule with a comparable molecular weight to vancomycin, but
much smaller than BSA (~22.4 nm3 & 66,463 Da), and frequently used
in cargo release experiments with silica particles [61,62].
Bio2-HF and MCM-41 were loaded both with fluorescein and
BSA and the release kinetics of each molecule was monitored
(Fig. 6(a&b)). MCM-41 exhibited highly different release kinetics for
fluorescein when it is loaded together with BSA (Fig. 7(a)). This can
probably be explained by the hindering effect of BSA and thus entrap-
ment of small fluorescein molecules in the micro/mesopores until BSA
molecules were detached from the surface of the particles. Therefore,
a lagging time in release of fluorescein was observed for MCM-41. In a
differentmanner, the release kinetics of fluorescein and BSAwas not af-
fected much when they are loaded together in the hierarchical pores of
the Bio2-HF. This allowed release of both large and small cargo mole-
cules at the same time can be beneficial in some combination therapy
applications. This explanation is not conclusive in demonstrating differ-
ential distribution of the drugs in hierarchical pores, and more studies
are needed to elucidate the real mechanism.
The release capabilities of mesoporous silica and SiOC particles were
tested in the presence of bacteria, S. aureus. Vancomycin-loadedmycin loaded nanoparticles in PBS buffer.
Fig. 6. The release profiles of (a) MCM-41, and (b) Bio2-HF when they are loaded with both fluorescein and BSA molecules simultaneously.
43C. Vakifahmetoglu et al. / Materials and Design 140 (2018) 37–44particles were added to 103 colony forming units (CFU) bacteria mix-
tures and the viability of the bacteria wasmonitored by culturemethod.
Bio2-HF andMCM-41 control particles sample were selected to be used
in this time-kill experiments since Bio2-HF demonstrated comparable
loading capacitywithMCM-41 (Fig. 4(b)). Thus, any difference between
two particles would indicate the efficiency of the drug release in killing
S. aureus. Time-kill curves were used to study the time course of antimi-
crobial effects [63].
Fig. 7 shows the effect of 1MIC concentration of vancomycin-loaded
MCM-41 or Bio2-HF and the change in density of live bacteria as a func-
tion of time. MIC values were determined according to the loaded con-
centration of vancomycin [39]. As can be seen in Fig. 7, vancomycin-
loaded particles can be considered an effective therapeutic strategy
against S. aureus, by inhibiting bacterial growth since the growth
curve started to level off after 2 h. A strong and prolonged bactericidal
activity from 2 to 24 hwas observed as compared to control experiment
without antibiotic application. Furthermore, the growth curve of
S. aureus in presence of vancomycin-loaded Bio2-HF was inhibited
slightly better compared to vancomycin-loaded MCM-41 (Fig. 7).
Time-kill results clearly demonstrated the bactericidal efficacy of
SiOC loaded with antibiotics and the effect was comparable to mesopo-
rous silica particles. The results also show a slightly better bactericidal
activity with vancomycin-loaded Bio2-HF compared to MCM-41. Com-
paring these two types of tested particles (MCM-41 and Bio2-HF) for ef-
fective inhibition of S. aureus growth, use of SiOC as controlled release
agents provides alternative opportunities. Due probably to theFig. 7. Time-kill curves for S. aureus cultures after treatingwith vancomycin-loadedMCM-
41 or Bio2-HF at 1 MIC concentration. Control refers to growth curve without any
vancomycin and MCM-41 or Bio2-HF refers to growth curves after addition of
vancomycin-loaded particles containing one MIC concentration.hierarchical porosity in Bio2-HF, the release behavior is different than
MCM-41 as shown in Fig. 7. From this perspective, succeeding quest ex-
ists: (i) for the design of PDC (both etched & un-etched state) based hi-
erarchical porosity, drug release systems loaded with multiple cargoes,
and (ii) for evaluation of their in-vitro properties (adsorption, time-
kill, etc.).
4. Conclusions
Hierarchically porous SiOC samples were made by using ‘molecular
spacer’ templated polymer followed by pyrolysis and hydrofluoric acid
etching. The samples showed high specific surface area (SSA) reaching
774 m2/g and multi-modal porosity. Such SSA samples were tested for
hemolytic behavior, then loading capabilities were measured with two
different polypeptides, vancomycin (MW = 1449 Da) and Bovine
Serum Albumin (BSA) (MW= 66,463 Da) having different molecular
sizes, and hence for their encapsulation efficiency, release kinetics and
biocompatibility. All SiOC samples showed lower hemolysis than that
of the commercially availablemesoporous silica (MCM-41). The loading
capacity studies revealed that one of the carbon-rich SiOC sample (Bio2-
HF) adsorbed about 3.8 times more BSA and about 1.4 times more van-
comycin molecules than MCM-41 particles. Samples showed similar
trends in release behavior, and HF treated samples demonstrated
~60% release, while MCM-41 was at ~80% after 24 h. Simultaneous
multi cargo loading and release capacity tests done by both fluorescein
and BSA, and the release kinetics of each molecule was monitored.
While a lagging time in release of fluorescein was observed for MCM-
41, not much change was observed when such molecules were loaded
together in the hierarchical pores of the Bio2-HF, demonstrating for
the first time the release of both large and small cargo molecules.
Time-kill (for effective inhibition of S. aureus growth) tests showed
that vancomycin-loaded Bio2-HF sample performed better than
vancomycin-loaded MCM-41 in improving bactericidal activity. This
study opens new prospects and demonstrates the potential for tailoring
custom-made drug (single & multi cargo) delivery components with
suitable hierarchical porosity.
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